BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    

VentriPoint Diagnostics to Present Clinical Validation Study at American College of Cardiology 59th Annual Scientific Session in March

1/27/2010 2:15:43 PM

SEATTLE, WASHINGTON--(Marketwire - January 27, 2010) - VentriPoint Diagnostics Ltd. (VentriPoint) (TSX VENTURE: VPT) today announced the abstract of a clinical validation study of the second application of the VentriPoint Medical System (VMS) will be presented at the American College of Cardiology's 59th Annual Scientific Session, March 14 to 16 in Atlanta, Georgia. The study demonstrates the accuracy of the method used by the VentriPoint Medical System (VMS) to generate critical heart measurements in three dimensions from two-dimensional ultrasound images with significantly greater speed and accuracy and at considerably lesser cost than is otherwise possible.

The research presented in this abstract, "Accuracy of Right Ventricular Volume and Function Analysis in Patients with Systemic Right Ventricles using Knowledge Based Reconstruction," is the result of an international collaboration effort to find a clinically feasible alternative to full manual tracings of heart borders from image data The VMS system was deployed successfully to calculate right ventricular volume on patients with a congenital heart defect in which the two major vessels that carry blood away from the heart - the aorta and the pulmonary artery - are transposed. In addition to accuracy and reproducibility, other advantages of the VMS are time and cost savings from reducing human labor in image analysis.

"Acceptance of this abstract by the American College of Cardiology demonstrates the interest in and clear need for an easy to use tool for monitoring right ventricular volume and function. These measurements are important for patient assessment and management," said Dr. David Sahn, the primary investigator of the study and the director of the OHSU Interdisciplinary Program for Cardiac Imaging and a noted expert in Congenital Heart Disease.

"The presentation of this research at such a prestigious meeting as the American College of Cardiology Annual Scientific Sessions represents a validation of our efforts to introduce the VMS for monitoring right ventricular volume and function from 2D ultrasound and MRI images," said Joe Ashley, VentriPoint's President and CEO. "We continue to pursue the requisite capital to commercialize our exceptionally accurate system to health professionals to aid them in diagnosing and treating cardiovascular disease."

More than one million adults and 800,000 children suffer from congenital heart disease in the U.S. alone, according to the American Heart Association and the Adult Congenital Heart Association. Studies are in progress at VentriPoint to expand the applications of the VMS system. The investigative team extends from the U.S. to sites in Canada, Great Britain, the Netherlands and Switzerland.

About VentriPoint Diagnostics Ltd

VentriPoint creates diagnostic tools to monitor patients with heart disease, the number one cause of death in developed countries. The VentriPoint Medical System is based upon technology licensed exclusively by VentriPoint from the University of Washington. The VMS is being adapted for a variety of heart-related diseases, with congenital heart disease representing the first application, and applications for pulmonary hypertension, cardiovascular disease and heart failure in process to follow. Canada and Europe have granted license approval for the VMS diagnostic tool, and VentriPoint timely responded to the U.S. Federal Drug Administration's 510(k) review by January 21, 2010.

To receive press releases, please email and mention VentriPoint in the Subject line.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, that address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may," "will," "anticipate," "believe," "estimate," "expect," "intend," and words of similar import are intended to identify any forward-looking statements. Do not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in VentriPoint's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. VentriPoint undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

VentriPoint Diagnostics
Ed Garth
Chief Financial Officer
(206) 283-0221, ext. 402
(206) 283-2309 (FAX)

CHF Investor Relations
Christopher Haldane
Account Manager
(416) 868-1079 ext.237
(416) 868-6198 (FAX)

Read at